ReviewCNS drugs2014
Cognitive effects of statin medications.
Review in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Statins for the prevention of dementia.The Cochrane database of systematic reviews · 2016Pooled it
- Protective effects of atorvastatin and rosuvastatin on 3,4-methylenedioxymethamphetamine (MDMA)-induced spatial learning and memory impairment.Inflammopharmacology · 2021Article
- Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults.Journal of the American College of Cardiology · 2021Observational
- Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors.Alzheimer's & dementia (New York, N. Y.) · 2021Review
- Blood Pressure and Statin Effects on Cognition: a Review.Current hypertension reports · 2019Review
- The role of APOE4 in Alzheimer's disease: strategies for future therapeutic interventions.Neuronal signaling · 2019Review
- Development of AD-Like Pathology in Skeletal Muscle.Journal of Parkinson's disease and Alzheimer's disease · 2019Article
- Effects of Plasma Lipids and Statins on Cognitive Function.Chinese medical journal · 2018Review
- The Effect of Statins on Rate of Cognitive Decline in Mild Cognitive Impairment.Alzheimer's & dementia (New York, N. Y.) · 2017Article
- Statin withdrawal in people with dementia.The Cochrane database of systematic reviews · 2016Review
- Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011.JAMA internal medicine · 2016Article
- Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.Cellular and molecular neurobiology · 2016Review
- Assessment of cognitive safety in clinical drug development.Drug discovery today · 2016Review
- PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.Drug safety · 2015Article
- Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer's disease.Journal of neurology & neurophysiology · 2014Article
- Role of endolysosomes and cholesterol in the pathogenesis of Alzheimer's disease: Insights into why statins might not provide clinical benefit.Austin journal of pharmacology and therapeutics · 2014Article
- Statins and cognitive impairment.Canadian family physician Medecin de famille canadien · 2014Article
- Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry.Behavioural brain research · 2014Article
- Altered Cholesterol Intracellular Trafficking and the Development of Pathological Hallmarks of Sporadic AD.Journal of Parkinson's disease and Alzheimer's diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Administration issued updated recommendations regarding statin medications, and the panel's comments regarding memory impairment fostered clinical confusion (in part because of the lay media's amplification). Cognitive data from several large epidemiological studies have not reliably demonstrated a robust association between incident cognitive impairment and statin use, with some studies reporting a protective effect, some reporting an increased risk and others finding no association. Although several interventional studies have evaluated statins as a possible adjunctive treatment for Alzheimer's disease, none have clearly demonstrated a benefit. A small number of case series have reported infrequent memory difficulties associated with statin use. In these series, the patients' cognitive symptoms resolved after statin discontinuation. The existing medical literature does not suggest that cognitive considerations should play a major role in medical decision making to prescribe statins for the large majority of patients. As with any medication prescribed for older adults, careful clinical monitoring for side effects should be exercised. If a patient is suspected of having idiosyncratic memory impairment associated with use of a statin medication, the drug can be discontinued. The patient should then be followed with careful clinical observation for 1-3 months for resolution of the cognitive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.